^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JS108

    i
    Other names: JS108, DAC-002, recombinant humanized anti-Trop2 mAb-Tub196 conjugate
    Associations

    News

    Trials
    Company:
    Hangzhou DAC Biotech, Shanghai Junshi Biosci
    Drug class:
    Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    10ms
    A Phase I Study of JS108 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=25, Terminated, Shanghai Junshi Bioscience Co., Ltd. | N=153 --> 25 | Trial completion date: Nov 2023 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Jun 2023; Sponsor has adjusted study development plan and terminated this clinical study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    JS108